For physicians

Stay current without searching the literature.

Every Monday, one email with the key new trials and reviews in the topics you choose.

Start free

Free until 31 December · No card required

See a weekly digest

An example from Cardiology. Yours is built from the topics you choose.

Papertis Weekly

Selected for you

Monday

Here are the top 3 this week.

European Heart JournalRandomized trial

Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in heart failure: the DECISION trial.

Key finding

Following blinded digoxin withdrawal, the incidence rate of cardiovascular death or worsening heart failure events rose to 42.8 versus 5.9 events per 100 patient-years in the placebo withdrawal arm (RR 7.37; 95% CI 1.56–34.88; P = .012), accompanied by increases in heart rate and NT-proBNP and a reduction in systolic blood pressure.

Also in the full summary

Practice impact: Relates to situations where discontinuation of long-term digoxin is being considered in patients with heart failure and a reduced or mildly reduced ejection fraction on contemporary guideline-recommended therapy.

Read the full summary →
JACCRandomized trial

Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF).

Key finding

At 6 months, heart failure was diagnosed in 24.6% of participants in the natriuretic peptide-based screening group versus 1% in the usual care group (OR: 58; 95% CI: 14–236; P < 0.001), with most newly identified cases being heart failure with preserved ejection fraction (23%).

Read the full summary →
JAMARandomized trial

Left Bundle-Branch Area Pacing vs Right Ventricular Pacing for Atrioventricular Block and Preserved Left Ventricular Function: The LEAP-Block Randomized Clinical Trial.

Key finding

In 482 randomized patients (mean age 67 years, 46% female), LBBAP reduced the 24-month composite primary endpoint of all-cause death, heart failure events, or upgrade to biventricular pacing compared with right ventricular pacing (2.4% vs 12.5%; absolute risk difference −10.1% [95% CI −16.8% to −3.4%]; HR 0.37 [95% CI 0.19–0.73]).

Read the full summary →
Open a full sample digest →
See an exceptional finding

Exceptional finding

Papertis alert, in your topics

ExceptionalNEJMPhase 3 RCT

Blinatumomab for replacing chemotherapy in pediatric acute lymphoblastic leukemia

Key finding

At a median follow-up of 2.9 years, 4-year event-free survival was 83.0% with blinatumomab vs 70.3% with standard chemotherapy (HR 0.51); treatment-related infections 23.9% vs 69.4%, neurotoxic events 12.0% vs 3.2%.

Why it matters

A randomized trial on a high-stakes treatment decision in pediatric high-risk B-cell ALL, with efficacy and safety data against standard chemotherapy.

View on PubMed →

Practice-changing papers don't wait for Monday: we email you as soon as we find one in your topics.

We screen papers from 3,000+ journals, including

NEJMThe LancetJAMABMJ

Free until 31 December 2026

No card required. Paid plans start in 2027.

Essential

US$3.49/month

Stay current in your specialty.

  • 3 topics of your choice
  • The best papers in your topics, every Monday
  • Ongoing clinical trials

Complete

US$6.99/month

Your whole field, at a glance.

  • Unlimited topics
  • Every new paper: the best in your digest, the rest in your dashboard
  • Exceptional findings: an alert when a practice-changing paper appears in your topics
  • Retraction alerts: if a paper you received is later retracted or corrected
  • Ongoing clinical trials

Your first digest arrives in minutes.

Pick your topics. Then every Monday, the key new papers.

Start free

Free until 31 December · No card required